|Targets||Neurokinin 1 Receptor|
|Description||Ibodutant is a tachykinin receptor antagonist. It selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. It is a candidate drug for irritable bowel syndrome diarrhea. It was developed by The Menarini Group. It is in the clinical phase III.|
|Solubility||Soluble in DMSO, not in water|
|Application||Ibodutant is a candidate drug for irritable bowel syndrome diarrhea.|
|Quality Standard||In-house standard|
|Boiling Point||921.8±65.0 °C | Condition: Press: 760 Torr|
|Melting Point||195-196 °C|
|Density||1.24±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Ibodutant was developed by The Menarini Group. It is in the clinical phase III.|
Orvepitant is a potent and selective Neurokinin-1 (NK1) antagonist. It may be potential therapeutic for the treatment of patients with major depressive disorder...
Serlopitant is a Neurokinin 1 (NK-1) receptor antagonist. Phase II clinical trials for the treatment of Prurigo nodularis and Pruritus are on-going.
Casopitant Mesylate is a potent, selective and orally active neurokinin 1 (NK1) receptor antagonist binding of the endogenous tachykinin neuropeptide substance ...
Fosnetupitant, a piperazine derivative, has been found to be a NK1 receptor antagonist that could be used in nausea and vomiting caused by chemotherapy. It was ...
Ibodutant is a tachykinin receptor antagonist. It selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations...
Orvepitant maleate is a neurokinin-1 (NK1) receptor antagonist developed for the treatment of depression and anxiety disease.
FR 113680 is a novel tripeptide substance P antagonist with NK1 receptor selectivity originated by Fujisawa for the treatment of Asthma. But no development are ...
Telmapitant is a neurokinin NK1 receptor antagonist.
The dihydrochloride salt form of Vofopitant, a tetrazole compound, has been found to be a neurokinin 1 antagonist that was once studied inbBipolar disorders as ...